Key result
Levosimendan administration prior to cardiopulmonary bypass did not significantly improve organ function compared to placebo, but reduced serious adverse events (13% vs 47%).
Why the study?
Does levosimendan reduce organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery?
Population
33 patients with left ventricular ejection fraction <30% scheduled for elective coronary artery bypass surgery
Comparison
Levosimendan (12.5 mg, 0.1 µg kg per min)… vs Placebo central venous infusion, immediately…
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
6 months
Authors
Loading...
Preoperative levosimendan did not reduce organ dysfunction in low-EF CABG; leaves optimal timing, dosing, and cardioprotective role open for further RCTs.
RCT (n=33)
double-blind
randomized
Does levosimendan reduce organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery?
p-value: p=NS
Prophylactic levosimendan in patients with severe LV dysfunction undergoing cardiac surgery does not preserve organ function but may reduce the need for postoperative inotropes and lower the incidence of serious adverse events.
Erb et al. (2014) conducted an RCT in Severely reduced left ventricular function undergoing cardiac surgery (n=33). Levosimendan vs. Placebo was evaluated on Organ dysfunction (Sequential Organ Failure Assessment scores) (p=NS). Levosimendan administration prior to cardiopulmonary bypass did not significantly improve organ function compared to placebo, but reduced serious adverse events (13% vs 47%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: